Koyfin Home > Directory > Health Care > Amphastar Pharma

Amphastar Pharma Price Chart AMPH

Historical daily share price chart and data for Amphastar Pharma since 2014 adjusted for splits and dividends. The latest closing price for Amphastar Pharma as of April 02, 2020 is $14.77.
  • In 2020 the stock opened at $19.44 and closed at $14.77 for a loss of -32% YTD.
  • In 2019 the stock opened at $19.65 and closed at $19.29 for a loss of -2%.
  • In 2018 the stock opened at $19.30 and closed at $19.90 for a gain of 3%.
  • In 2017 the stock opened at $18.61 and closed at $19.24 for a gain of 3%.
View Chart On Koyfin

Amphastar Pharma Summary

Stock Symbol: AMPH

Amphastar Pharma Company Info

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products. It offers enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; naloxone for opioid overdose; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; lidocaine jelly, a local anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection for newborn babies; and morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures. In addition, it offers procainamide for documented ventricular arrhythmias; neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy; and isoproterenol hydrochloride injection for mild or transient episodes of heart block, as well as recombinant human and porcine insulins. Further, the company has a pipeline of 20 product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Market Cap
Dividend Yield
0 %
Beta vs SPX
Short Interest
294.45 %
30D Volatility
Hedge Fund Held
0 %

Last 10 Days of AMPH Prices